Co-Authors
This is a "connection" page, showing publications co-authored by JOSEPH KHOURY and STEVEN M KORNBLAU.
Connection Strength
0.792
-
Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391.
Score: 0.204
-
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
Score: 0.163
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.057
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.053
-
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.
Score: 0.052
-
Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428.
Score: 0.050
-
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
Score: 0.049
-
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
Score: 0.042
-
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
Score: 0.042
-
Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
Score: 0.041
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.039